BioArctic Interim Report for the period October - December 2025
PR Newswire —
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US Leqembi...